WFA
HZNP

Wipfli Financial Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Wipfli Financial Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$79K Buy
+1,283
New +$89.6K 0.01% 848

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wipfli Financial Advisors's HZNP Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022: 1,283 shares worth $79K. The stake represents 0.01% of the portfolio and ranks #848 among its holdings.

530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

  • Wipfli Financial Advisors held 1,283 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $79K as of Q3 2022.
  • Horizon Therapeutics Public Limited Company Ordinary Shares was a new Wipfli Financial Advisors position in Q3 2022.
  • Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #848 holding.
  • 530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.